Class summary at a glance.

Every drug in the Platinum-based Drug class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $1.8Mcombined across class
Total Rx claims: 12K4K unique beneficiaries
Generic mfrs (active): 31across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Oxaliplatin

5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2009-08-10

13 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $1.5M

Class share

81%

of class CY24 spend

View profile →

Carboplatin

Brand: KYXATA · 6K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2004-10-14

12 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend $293258

Class share

16%

of class CY24 spend

View profile →

Cisplatin

1K Part D claims (CY24) · 432 beneficiaries · First FDA approval: 2000-06-01

6 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $58465

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.